BTIG Research Raises GE HealthCare Technologies (NASDAQ:GEHC) Price Target to $91.00

GE HealthCare Technologies (NASDAQ:GEHC) had its price objective upped by equities research analysts at BTIG Research from $87.00 to $91.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 9.79% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Citigroup upped their price target on shares of GE HealthCare Technologies from $83.00 to $88.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. UBS Group lowered GE HealthCare Technologies from a “neutral” rating to a “sell” rating and upped their price objective for the stock from $73.00 to $77.00 in a research note on Thursday, January 15th. Bank of America upped their price target on shares of GE HealthCare Technologies from $82.00 to $92.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Evercore ISI restated an “outperform” rating and set a $95.00 target price on shares of GE HealthCare Technologies in a research report on Monday, January 5th. Finally, Wells Fargo & Company decreased their price target on shares of GE HealthCare Technologies from $89.00 to $87.00 and set an “overweight” rating on the stock in a research note on Thursday, October 30th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $90.67.

GE HealthCare Technologies Stock Performance

Shares of GEHC stock traded up $4.10 during trading hours on Wednesday, reaching $82.88. The company had a trading volume of 2,573,897 shares, compared to its average volume of 3,471,408. The firm has a market cap of $37.76 billion, a PE ratio of 17.10, a price-to-earnings-growth ratio of 2.42 and a beta of 1.08. The business has a fifty day moving average price of $82.64 and a 200-day moving average price of $77.43. GE HealthCare Technologies has a one year low of $57.65 and a one year high of $94.80. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.95 and a current ratio of 1.18.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Wednesday, February 4th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.01. The business had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.60 billion. GE HealthCare Technologies had a net margin of 10.94% and a return on equity of 22.52%. The firm’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.45 EPS. GE HealthCare Technologies has set its FY 2026 guidance at 4.950-5.150 EPS. Sell-side analysts predict that GE HealthCare Technologies will post 4.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GE HealthCare Technologies

A number of large investors have recently made changes to their positions in GEHC. Dodge & Cox boosted its holdings in GE HealthCare Technologies by 42.1% during the 2nd quarter. Dodge & Cox now owns 23,567,950 shares of the company’s stock valued at $1,745,678,000 after acquiring an additional 6,982,441 shares during the period. Norges Bank purchased a new position in GE HealthCare Technologies during the 2nd quarter valued at about $468,120,000. Capital Research Global Investors boosted its stake in shares of GE HealthCare Technologies by 25.0% during the third quarter. Capital Research Global Investors now owns 24,972,556 shares of the company’s stock valued at $1,875,400,000 after purchasing an additional 4,998,154 shares in the last quarter. Boston Partners purchased a new stake in GE HealthCare Technologies during the third quarter worth $287,627,000. Finally, Holocene Advisors LP increased its holdings in shares of GE HealthCare Technologies by 178.5% in the 2nd quarter. Holocene Advisors LP now owns 4,027,352 shares of the company’s stock valued at $298,306,000 after acquiring an additional 2,581,522 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Q4 results narrowly beat expectations — EPS $1.44 vs. $1.43 consensus and revenue $5.70B vs. $5.60B, showing 7.1% year-over-year revenue growth; this validates near-term execution. GE HealthCare Technologies (GEHC) Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Company forecasted 2026 profit above Wall Street estimates, citing strong demand for diagnostic and imaging devices — this raised the forward outlook and supports higher valuation expectations. GE HealthCare forecasts 2026 profit above estimates on strong demand for medical devices
• Positive Sentiment: Regulatory and product momentum: FDA clearance and CE mark for the Allia Moveo mobile C-arm (AI guidance, compact design) enable commercialization and early global installs — a tangible growth driver for imaging sales. GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut
• Neutral Sentiment: Company-released full Q4 and FY2025 results and commentary reiterate strategic focus on precision care, growth acceleration and business optimization — informative for modeling but largely consistent with the beats/guidance. GE HealthCare reports fourth quarter and full year 2025 financial results
• Neutral Sentiment: Analyst commentary and features frame GEHC as a long-term value/growth opportunity but note that near-term decisions depend on margin trends and capital allocation — useful context for longer-horizon investors. Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
• Negative Sentiment: Profitability caveat: the WSJ notes Q4 profit fell despite higher revenue, and management described a “dynamic macroeconomic environment” — a reminder margins and cost pressures could limit upside if growth slows or costs rise. GE HealthCare Technologies Posts Lower Profit, Despite Higher Revenue
• Negative Sentiment: Analyst preview flagged risks from tariffs and ongoing investments that could keep margins under pressure even as revenue grows — watch margin guidance and gross-margin trends in upcoming quarters. GE HealthCare Stock Before Q4 Earnings: To Buy or Not to Buy?

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.